Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,569.78 -24.85 (-0.54%) Dow
36,204.44 -41.06 (-0.11%) Nasdaq
14,185.49 -119.54 (-0.84%) Bitcoin USD
41,799.21 +2,205.42 (+5.57%) CMC Crypto 200
859.38 +0.67 (+0.08%)
Vir Biotechnology, Inc. (VIR)
After hours:
- Business Wire
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, November 13, 2023--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
- Business Wire
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, November 10, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and o
- Business Wire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
SAN FRANCISCO, November 08, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years.
